Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

zolpimist

  • Home
  •  
  • zolpimist



  • Most Read
  • Latest Comments
  • Arovella is helping insomnia sufferers get some shut eye
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Arovella is helping insomnia sufferers get some shut eye
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Arovella is helping insomnia sufferers get some shut eye
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Arovella is helping insomnia sufferers get some shut eye
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Arovella is helping insomnia sufferers get some shut eye
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Arovella is helping insomnia sufferers get some shut eye
    • News

    Arovella is helping insomnia sufferers get some shut eye

    You know those nights. The ones where you toss and turn, where it’s too hot, or too cold. The ones where you count sheep, stare at the ceiling, and eventually abandon your attempt at sleep to go eat cheese out of the bag at midnight (just admit it, we all do it). Some have these

    Read More
    Public
  • SUDA gains regulatory approval for sale of insomnia treatment spray
    • News

    SUDA gains regulatory approval for sale of insomnia treatment spray

    Australians suffering from insomnia could soon have relief from the disorder with SUDA Pharmaceuticals (ASX: SUD) gaining approval from the Therapeutics Goods Administration (TGA) for the sale of their ZolpiMist spray as a treatment for short-term insomnia.  The regulatory approval enables ZolpiMist to be sold in Australia and will assist their strategic partners in other

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.